Hugel Inc., a leading global medical aesthetics company publicly traded in South Korea, announced that industry veteran Carrie Strom has been appointed President and Global Chief Executive Officer, and is expected to be appointed to the Board of Directors following approval at a forthcoming shareholders' meeting. Strom will start the newly established global CEO role on October 13, 2025. The Hugel Inc. executive leadership team will report directly to Strom, including the recently appointed head of Hugel Korea, Daniel Chang.

Most recently, Strom served as Senior Vice President of AbbVie and Global President of Allergan Aesthetics from May 2020 to February 2025, where she managed the $5 billion aesthetics portfolio, including Botox Cosmetic and Juvéderm, across more than 50 global markets. Previously, she was Senior Vice President of Allergan's US Medical Aesthetics business, and before that, she spent 11 years at Pfizer in various sales and marketing roles.

"I am honored to join Hugel as the CEO and look forward to working alongside the talented and dedicated employees, operating team, and board of directors," said Strom. "Hugel offers market-leading aesthetic products driven by science and the highest quality, which have always been grounded in Korean beauty standards. My priority is to build on Hugel's leadership in South Korea and transform it into a global aesthetics powerhouse, raising the bar for how we serve customers and patients around the world."

Hugel has rapidly expanded its global footprint, now marketing its botulinum toxin products (known as Botulax or Letybo globally) in 69 countries and its dermal fillers in 53 countries. As the market-leading botulinum toxin brand in South Korea, Hugel is the only South Korean company to have regulatory approvals in the world's three largest markets: the US, China, and Europe.

Read more at PR Newswire >>